|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Moving Averages||Sell||Buy||Strong Buy||Buy||Buy|
|Technical Indicators||BUY||BUY||Strong Buy||BUY||Strong Buy|
|Summary||Neutral||Buy||Strong Buy||Buy||Strong Buy|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Three Outside Up||1M||1||Jan 18|
|Bullish Engulfing||1M||2||Dec 17|
|Engulfing Bearish||1H||2||Feb 16, 2018 01:00PM|
|Himadri Speciality Chem||161.80||168.75||158.65||-2.85||-1.73%||1.38M||10:26:51|
|Punjab National Bank||116.50||123.50||113.55||-10.45||-8.32%||130.90M||10:29:38|
|Tata Steel Ltd||648.85||693.40||639.00||-40.75||-5.91%||17.66M||10:29:37|
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.Read More
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||Start Trading|
|U.S. Commodity Futures Trading Commission (United States)||Start Trading|
|U.S. Commodity Futures Trading Commission (United States)||$250||Start Trading|
|National Futures Association (United States), U.S. Commodity Futures Trading Commission (United States), The Financial Conduct Authority (United Kingdom), Australian Securities and Investments Commission (Australia), Financial Industry Regulatory Authority (United States), Investment Industry Regulatory Organization of Canada (Canada), Securities and Exchange Board of India (India), Securities and Exchange Commission (United States), The Securities and Futures Commission (Hong Kong), Securities Investor Protection Corporation (United States)||$10000||Start Trading|
Add a Comment
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.